Evidence map›Paper›PMID 33308298›Full record

ArticleJournal of experimental & clinical cancer research : CR2020

CircCDKN2B-AS1 interacts with IMP3 to stabilize hexokinase 2 mRNA and facilitate cervical squamous cell carcinoma aerobic glycolysis progression.

Yanan Zhang, Lu Zhao, Shizhou Yang, Yixuan Cen, Tingjia Zhu, Lingfang Wang, Lili Xia, Yuwan Liu, Jian Zou, Junfen Xu and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. CircFBXW4 Suppresses Colorectal Cancer Progression by Regulating the MiR-338-5p/SLC5A7 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Yanan ZhangWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Lu ZhaoWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Shizhou YangDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China.
Yixuan CenWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Tingjia ZhuWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Lingfang WangWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Lili XiaWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Yuwan LiuWomen's Reproductive Health Laboratory of Zhejiang Province; Women's Hospital; School of Medicine, Zhejiang University, Hangzhou, 310006, China.
Jian ZouDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China.
Junfen XuDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China.
Yang LiDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China.
Xiaodong ChengDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China.
Weiguo LuDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China.
Xinyu WangDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China. wangxy@zju.edu.cn.
Xing XieDepartment of Gynecologic Oncology; Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, No.1 Xueshi Road, Hangzhou, 310006, China. xiex@zju.edu.cn.
Women's Hospital, School of Medicine, Zhejiang University · CNZhejiang University · CNWomen's Hospital · US

Funding

Medical and Health science and Technology project of Zhejiang Province 2017KY099National Natural Science Foundation of China 82072855NSF of China 81702552Postdoctoral Science Foundation 2017M621954the Fundamental Research Funds for the Central Universities 2017XZZX001-01the Fundamental Research Funds for the Central Universities 2019QNA7035the Key research and development plan in Zhejiang province No. 2020C03025the National Key Research and Development Program of China No. 2016YFC1302900the Natural Science Foundation of Zhejiang Province No. LQ20H160049
6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) have been reported to play key roles in the development of various cancers. However, the biological functions and clinical significance of most circRNAs are still elusive. The purpose of this study was to explore the function and mechanism of a certain circRNA named circCDKN2B-AS1 in cervical cancer development and its potential value in the clinic.

methodsqRT-PCR was used to verify the expression level of circCDKN2B-AS1. CCK-8, Transwell, and flow cytometry (FCM) assays were performed to detect cellular proliferation, migration, and apoptosis, respectively. A Seahorse XFe96 Analyzer was used to measure glycolysis metabolism level. RNA pull-down, RNA immunoprecipitation (RIP), actinomycin-D addition assays and Western blotting were used to screen and elucidate the potential mechanisms involved. BALB/c nude mice and zebrafish embryos (AB, WT) were used as animal models to investigate tumorigenesis capability.

resultsCircCDKN2B-AS1, a circular isoform of the long noncoding RNA (lncRNA) CDKN2B-AS1, was upregulated in cervical cancer and precancerous tissues. We found that circCDKN2B-AS1 associated with the IMP3 protein depending on a specific binding site and regulated the stability of Hexokinase 2 (HK2) mRNA, the rate-limiting enzyme of the aerobic glycolysis pathway. The expression level of circCDKN2B-AS1 fated the binding of IMP3 to the 3' untranslated region (UTR) of HK2 mRNA, consequently affecting the malignant cell phenotype and aerobic glycolysis in cervical cancer in vitro and in vivo. Mutant circCDKN2B-AS1, lacking the IMP3 binding site, did not have such effects. Utilization of an inhibitory peptide to block the interaction between circCDKN2B-AS1 and the IMP3 protein impeded the binding of IMP3 to the 3'UTR of HK2 mRNA and suppressed aerobic glycolysis in cervical cancer cells.

conclusionsOur findings demonstrate that circCDKN2B-AS1 facilitates aerobic glycolysis by sponging the IMP3 protein to stabilize HK2 mRNA, consequently promoting the malignant phenotype in cervical cancer, which may provide a potential approach for cervical cancer therapeutics.

Indexed as

GlycolysisAdultAnimalsApoptosisBiomarkers, TumorCarcinoma, Squamous CellCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHexokinaseHumansMiceMice, Inbred BALB CMice, NudeBiomarkers, TumorCDKN2B antisense RNA, humanHexokinaseHK2 protein, humanIMP3 protein, humanRibonucleoproteins, Small NucleolarRNA, CircularRNA, Long NoncodingRNA, MessengerAerobic glycolysisCervical cancerCircCDKN2B-AS1CircRNAHK2IMP3

Identifiers

PMID33308298
PMCPMC7731507
OpenAlexW3109774381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.